+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gynecological Cancer Drugs Market by End User, Distribution Channel, Administration Route, Drug Class, Cancer Type - Global Forecast to 2030- Product Image
Gynecological Cancer Drugs Market by End User, Distribution Channel, Administration Route, Drug Class, Cancer Type - Global Forecast to 2030- Product Image
Sale

Gynecological Cancer Drugs Market by End User, Distribution Channel, Administration Route, Drug Class, Cancer Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887490
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gynecological Cancer Drugs Market grew from USD 10.35 billion in 2024 to USD 11.63 billion in 2025. It is expected to continue growing at a CAGR of 12.22%, reaching USD 20.68 billion by 2030.

Redefining the Gynecological Cancer Therapeutics Landscape

The landscape of gynecological oncology is in a state of profound evolution. As incidence rates of cervical, endometrial, ovarian and vulvar cancers persist, advances in molecular science and therapeutic delivery have sparked a wave of innovation. This report opens by situating the current therapeutic environment within historical trends in treatment efficacy, safety and patient outcomes. By tracing the arc from conventional chemotherapy regimens to the emergence of targeted agents and immuno-based therapies, we establish the groundwork for understanding how clinical priorities and patient needs have shifted.

Armed with this context, we underscore the urgency for stakeholders to navigate rising regulatory complexity, growing demand for personalized solutions and the pressures of escalating development costs. The introduction frames both the promise of transformative treatments-such as PARP inhibitors and checkpoint inhibitors-and the formidable challenges that remain in bringing these advances to all patient populations. By grounding the narrative in the latest peer-reviewed findings and real-world evidence, this section sets the stage for a data-driven exploration of market dynamics, competitive positioning and strategic imperatives that follow.

Emerging Paradigms Shaping Treatment Pathways

In recent years, the gynecological cancer space has witnessed a series of paradigm-shifting developments. Precision oncology has moved from concept to clinic as biomarker-driven therapies demonstrate superior outcomes in ovarian and endometrial malignancies. Advances in next-generation sequencing have accelerated patient stratification, enabling checkpoint inhibitors to gain traction among individuals with high microsatellite instability.

Meanwhile, emerging combination regimens blending immunotherapy with anti-angiogenic compounds or PARP inhibitors have begun to redefine standards of care. Regulatory bodies have responded with expedited approval pathways and adaptive trial frameworks, reflecting an industry-wide commitment to faster patient access. Concurrently, digital health platforms and wearable devices are reshaping monitoring protocols, facilitating remote adherence tracking and early detection of adverse events. Collectively, these shifts highlight a future in which multidimensional treatment strategies converge to deliver more durable responses while maintaining tolerability, marking a new chapter in gynecological oncology management.

Navigating the 2025 US Tariff Wave Impact

The introduction of new tariffs on imported active pharmaceutical ingredients and finished formulations in 2025 has introduced a complex set of headwinds for manufacturers and supply-chain stakeholders. As duties drive up input costs, companies face pressure to recalibrate sourcing strategies, renegotiate provider contracts and reevaluate pricing structures to protect margins without compromising patient access.

In response, several leading innovators have accelerated investments in regional API production hubs and diversified supplier networks, mitigating exposure to single-country dependencies. At the same time, downstream players including hospital pharmacies and specialty distributors are grappling with inventory allocation challenges and potential reimbursement constraints. These cumulative tariff impacts underscore the necessity for integrated risk-management frameworks and agile procurement processes. By tracking duty fluctuations in real time and leveraging predictive analytics, market participants can anticipate cost spikes and optimize their operations to sustain both profitability and continuity of care.

Unveiling Core Market Segmentation Dynamics

A nuanced understanding of market segmentation is instrumental in crafting precise commercial and clinical strategies. When examining end-user dynamics, oncology clinics and outpatient clinics have emerged as high-velocity channels for early-stage interventions, whereas private and public hospitals continue to drive volume for complex infusion therapies. Distribution channel analysis reveals that hospital pharmacies often serve as the primary conduit for in-hospital administrations, while retail and online pharmacies cater to the growing oral therapy market by offering convenience and broader geographic reach.

Administration routes have likewise shaped treatment adoption curves. Intraperitoneal delivery, once niche, is gaining traction for targeted localized therapy, while bolus and infusion regimens under the intravenous umbrella remain foundational for platinum-based compounds. Oral capsules and tablets have empowered more patients to transition to home-based care, enhancing adherence and quality of life. Within the drug class spectrum, chemotherapy agents anchored by alkylating agents, platinum compounds and taxanes maintain a leading share, but targeted therapies-particularly angiogenesis inhibitors, PARP inhibitors and tyrosine kinase inhibitors-are rapidly expanding their foothold. Immunotherapy checkpoint inhibitors and vaccine candidates are carving out novel niches, complemented by hormonal therapies exploiting anti-estrogens and aromatase inhibitors. Finally, disease-type segmentation clarifies that ovarian and cervical cancer therapeutics dominate clinical investment, with increasing focus now shifting to endometrial and vulvar indications as trial pipelines mature.

Divergent Opportunities Across Global Regions

Regional market dynamics exhibit distinct profiles that demand tailored approaches. In the Americas, robust research infrastructure, comprehensive reimbursement frameworks and high adoption rates of next-generation therapies have positioned the region as a bellwether for clinical innovation. By contrast, Europe, Middle East and Africa present a more heterogeneous environment in which regulatory harmonization efforts coexist with pockets of access disparity, prompting manufacturers to deploy differentiated pricing and value-based contracting models.

Asia-Pacific is characterized by rapid expansion of healthcare capacity, driven by government initiatives to broaden oncology services and local manufacturing incentives. This market is particularly receptive to cost-effective oral regimens and partnership models that facilitate technology transfer. Recognizing these divergent regional dynamics allows stakeholders to align their go-to-market strategies with localized reimbursement landscapes, infrastructure maturity and patient access priorities.

Profiling Market Innovators and Strategic Alliances

Leading firms in the gynecological cancer drugs arena are leveraging complementary portfolios and strategic partnerships to stay ahead of the curve. Major pharmaceutical companies have bolstered their pipelines through targeted acquisitions of biotech innovators specializing in PARP inhibitors and checkpoint inhibitors, while forging global licensing agreements to expand geographic reach. Collaborations between established oncology leaders and specialized contract research organizations have streamlined trial execution and accelerated data generation.

At the same time, nimble biotechs are carving out niches by advancing first-in-class molecules through adaptive trial designs, often backed by precision medicine spin-outs. The interplay between these diverse players fosters a competitive yet collaborative ecosystem in which co-development initiatives and value-sharing arrangements are increasingly common. Observing these corporate maneuvers provides critical insight into the pathways through which novel assets can traverse from research labs to the clinic, shaping the competitive landscape for years to come.

Strategic Imperatives for Industry Leaders

Industry leaders must adopt a multifaceted playbook to capture emerging opportunities and counteract market pressures. Strengthening regional manufacturing capabilities and forging strategic supplier partnerships will serve as the foundation for supply-chain resilience in the face of tariff fluctuations. Investing in biomarker discovery and companion diagnostic collaborations will further differentiate product offerings and facilitate premium positioning in value-based care environments.

Moreover, engaging payers early through outcome-driven contracting and real-world evidence generation can unlock broader patient access while mitigating reimbursement risks. Digital health integration-from telemonitoring to adherence support-will enhance patient engagement and inform continuous product optimization. Finally, expanding footprints in high-growth geographies requires culturally attuned market entry strategies and flexible pricing frameworks. By aligning these imperatives, companies can achieve sustainable growth while advancing the standard of care for patients worldwide.

Rigorous Analytical Framework and Data Collection Protocols

This analysis is underpinned by a rigorous methodology combining primary interviews with oncologists, payers, distributors and patient advocacy organizations, alongside an exhaustive review of regulatory filings, clinical trial registries and peer-reviewed journals. Data triangulation techniques were employed to validate insights across multiple sources, ensuring robustness and credibility. Secondary research encompassed annual reports, financial disclosures and industry white papers to map competitive positioning and deal activity.

Proprietary databases were leveraged to trace drug pipelines, patent landscapes and licensing agreements. Qualitative inputs were enriched by expert panels convened to challenge assumptions and refine scenario analyses. All findings underwent comprehensive validation through cross-functional stakeholder review, guaranteeing accuracy in reflecting the evolving dynamics of the gynecological oncology market.

Converging Trends and Future Horizons in Gynecological Oncology

The convergence of precision medicine, innovative delivery modalities and shifting payer paradigms heralds a new era in gynecological cancer therapeutics. While challenges related to affordability, supply-chain resilience and regulatory complexity persist, the momentum behind targeted therapies and immuno-oncology solutions is undeniable. Key players are poised to capitalize on biomarker-driven strategies, digital health integration and strategic alliances that accelerate development timelines and broaden patient access.

As the market continues to mature, agility will be paramount-requiring stakeholders to anticipate tariff fluctuations, adapt to regional heterogeneity and invest in evidence-based value demonstrations. Through strategic foresight and collaborative execution, the industry can deliver on its promise of more effective, safer and personalized treatments for women affected by these cancers.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • End User
    • Clinics
      • Oncology Clinics
      • Outpatient Clinics
    • Hospitals
      • Private Hospitals
      • Public Hospitals
    • Specialty Centers
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Administration Route
    • Intraperitoneal
    • Intravenous
      • Bolus
      • Infusion
    • Oral
      • Capsule
      • Tablet
  • Drug Class
    • Chemotherapy Agents
      • Alkylating Agents
      • Platinum Compounds
      • Taxanes
    • Hormonal Therapy
      • Anti-Estrogens
      • Aromatase Inhibitors
    • Immunotherapy
      • Checkpoint Inhibitors
      • Vaccines
    • Targeted Therapy
      • Angiogenesis Inhibitors
      • PARP Inhibitors
      • Tyrosine Kinase Inhibitors
  • Cancer Type
    • Cervical Cancer
    • Endometrial Cancer
    • Ovarian Cancer
    • Vulvar Cancer
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Clovis Oncology, Inc.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Eisai Co., Ltd
  • Amgen Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gynecological Cancer Drugs Market, by End User
8.1. Introduction
8.2. Clinics
8.2.1. Oncology Clinics
8.2.2. Outpatient Clinics
8.3. Hospitals
8.3.1. Private Hospitals
8.3.2. Public Hospitals
8.4. Specialty Centers
9. Gynecological Cancer Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Gynecological Cancer Drugs Market, by Administration Route
10.1. Introduction
10.2. Intraperitoneal
10.3. Intravenous
10.3.1. Bolus
10.3.2. Infusion
10.4. Oral
10.4.1. Capsule
10.4.2. Tablet
11. Gynecological Cancer Drugs Market, by Drug Class
11.1. Introduction
11.2. Chemotherapy Agents
11.2.1. Alkylating Agents
11.2.2. Platinum Compounds
11.2.3. Taxanes
11.3. Hormonal Therapy
11.3.1. Anti-Estrogens
11.3.2. Aromatase Inhibitors
11.4. Immunotherapy
11.4.1. Checkpoint Inhibitors
11.4.2. Vaccines
11.5. Targeted Therapy
11.5.1. Angiogenesis Inhibitors
11.5.2. PARP Inhibitors
11.5.3. Tyrosine Kinase Inhibitors
12. Gynecological Cancer Drugs Market, by Cancer Type
12.1. Introduction
12.2. Cervical Cancer
12.3. Endometrial Cancer
12.4. Ovarian Cancer
12.5. Vulvar Cancer
13. Americas Gynecological Cancer Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Gynecological Cancer Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Gynecological Cancer Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. AstraZeneca PLC
16.3.3. Merck & Co., Inc.
16.3.4. GlaxoSmithKline plc
16.3.5. Clovis Oncology, Inc.
16.3.6. Pfizer Inc.
16.3.7. Novartis AG
16.3.8. Johnson & Johnson
16.3.9. Eisai Co., Ltd
16.3.10. Amgen Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GYNECOLOGICAL CANCER DRUGS MARKET MULTI-CURRENCY
FIGURE 2. GYNECOLOGICAL CANCER DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. GYNECOLOGICAL CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GYNECOLOGICAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GYNECOLOGICAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GYNECOLOGICAL CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY BOLUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TAXANES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANTI-ESTROGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY AROMATASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 82. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 84. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 85. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 87. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 88. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 89. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 91. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 92. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 93. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 94. CANADA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 100. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 102. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 105. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 106. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 107. MEXICO GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 161. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 163. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 164. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 166. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 167. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 168. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 170. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 171. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 172. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 173. GERMANY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 174. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 179. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 180. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 181. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 183. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 184. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 185. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 186. FRANCE GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 200. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 202. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 203. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 205. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 206. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 207. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 208. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 209. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 210. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 212. ITALY GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 213. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 215. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 216. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 218. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 219. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 220. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 222. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 223. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 224. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 225. SPAIN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 265. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 267. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 268. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 270. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 271. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 272. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 273. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 274. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 275. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 276. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 277. DENMARK GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 281. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 291. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 292. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 293. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 294. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 296. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 297. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 298. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 299. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 300. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 301. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 302. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 303. QATAR GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 304. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 306. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 309. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, 2018-2030 (USD MILLION)
TABLE 310. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 311. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 312. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2030 (USD MILLION)
TABLE 313. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, 2018-2030 (USD MILLION)
TABLE 314. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 315. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 316. FINLAND GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 317. SWEDEN GYNECOLOGICAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Gynecological Cancer Drugs market report include:
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Clovis Oncology, Inc.
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Eisai Co., Ltd
  • Amgen Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.63 Billion
Forecasted Market Value ( USD ) by 2030 $ 20.68 Billion
Compound Annual Growth Rate12.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gynecological Cancer Drugs - Global Strategic Business Report - Product Image

Gynecological Cancer Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Gynecological Cancer Drugs Market Report 2025 - Product Image

Gynecological Cancer Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Women's Health Therapeutics Market by Therapeutic Area, Product Type, Distribution Channel, End-User - Global Forecast to 2030 - Product Image

Women's Health Therapeutics Market by Therapeutic Area, Product Type, Distribution Channel, End-User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Next-Generation Gynecological Cancer Diagnostics Market by Technology, Application, Product, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Next-Generation Gynecological Cancer Diagnostics Market by Technology, Application, Product, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Gynecology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Gynecology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From

About the Gynecological Cancer Drugs Market

The Gynecological Cancer Drugs market is a specialized segment within the broader domain of Oncology Drugs, focusing on medications used in the prevention and treatment of cancers affecting the female reproductive organs. This category encompasses drugs for ovarian, cervical, uterine/endometrial, and other less common gynecologic cancers. Advances in the understanding of the pathophysiology of gynecologic cancers have led to the development of targeted therapies, immunotherapy, hormone therapies, and chemotherapy agents. The growth in this market is driven by a rising prevalence of gynecological cancers, increased awareness of women's health, and ongoing research and development leading to more precise and personalized treatment options. In the landscape of the Oncology Drugs sector, gynecological cancer treatments are vital because they address a distinct and critical patient population. Various market participants often collaborate with research institutions and engage in clinical trials to enhance existing treatments and innovate new therapeutic solutions, facilitating progress in women's oncological care. Prominent companies operating in the Gynecological Cancer Drugs market include Roche Holding AG, AstraZeneca, Novartis AG, Pfizer Inc., and Bristol-Myers Squibb Company. These firms are pivotal in the research and production of drugs that cater to gynecological oncology, continually advancing the standards of care through therapeutic breakthroughs and extensive research initiatives. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.